AU2004283925A1 - Use of metallic cations to improve functional activity of antibodies - Google Patents

Use of metallic cations to improve functional activity of antibodies Download PDF

Info

Publication number
AU2004283925A1
AU2004283925A1 AU2004283925A AU2004283925A AU2004283925A1 AU 2004283925 A1 AU2004283925 A1 AU 2004283925A1 AU 2004283925 A AU2004283925 A AU 2004283925A AU 2004283925 A AU2004283925 A AU 2004283925A AU 2004283925 A1 AU2004283925 A1 AU 2004283925A1
Authority
AU
Australia
Prior art keywords
antibody
antibodies
zinc
anyone
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004283925A
Other languages
English (en)
Inventor
Dominique Bourel
Frederic Ducancel
Arnaud Glacet
Sylvie Jorieux
Enrico Stura
Jean-Luc Teillaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB Biotechnologies SAS
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Publication of AU2004283925A1 publication Critical patent/AU2004283925A1/en
Assigned to LFB BIOTECHNOLOGIES reassignment LFB BIOTECHNOLOGIES Request for Assignment Assignors: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2004283925A 2003-10-20 2004-10-20 Use of metallic cations to improve functional activity of antibodies Abandoned AU2004283925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0312228 2003-10-20
FR0312228A FR2861079B1 (fr) 2003-10-20 2003-10-20 Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
PCT/FR2004/002687 WO2005040216A2 (fr) 2003-10-20 2004-10-20 Utilisation de cations metalliques pour cristalliser le fragment fc d’un anticorps rhesus d

Publications (1)

Publication Number Publication Date
AU2004283925A1 true AU2004283925A1 (en) 2005-05-06

Family

ID=34385293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283925A Abandoned AU2004283925A1 (en) 2003-10-20 2004-10-20 Use of metallic cations to improve functional activity of antibodies

Country Status (8)

Country Link
EP (1) EP1689785A2 (fr)
JP (1) JP2007537990A (fr)
AU (1) AU2004283925A1 (fr)
BR (1) BRPI0415620A (fr)
CA (1) CA2542928A1 (fr)
FR (1) FR2861079B1 (fr)
IL (1) IL175026A0 (fr)
WO (1) WO2005040216A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2787006B1 (fr) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anticorps anti-CD8 dont la liaison dépend de Ca2+

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081213A1 (fr) * 1990-05-08 1991-11-09 Richard A. Lerner Proteines capables de liaison avec les metaux
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs

Also Published As

Publication number Publication date
IL175026A0 (en) 2006-08-20
JP2007537990A (ja) 2007-12-27
FR2861079B1 (fr) 2007-09-28
FR2861079A1 (fr) 2005-04-22
WO2005040216A2 (fr) 2005-05-06
WO2005040216A3 (fr) 2005-10-20
EP1689785A2 (fr) 2006-08-16
BRPI0415620A (pt) 2006-12-12
CA2542928A1 (fr) 2005-05-06

Similar Documents

Publication Publication Date Title
AU2022231722A1 (en) Humanized and affinity matured antibodies to FcRH5 and methods of use
AU2004283924B2 (en) Correlation between the fucose content / galactose content ratio of anti-rhesus-D and anti-HLA-DR antibodies and the ADCC activity
US20090029393A1 (en) Method for preparing antibodies selective for activating fc receptors
DK2380910T3 (en) Antigen binding molecules with increased Fc receptor binding affinity and effector function
AU2006290433B2 (en) Modified antigen binding molecules with altered cell signaling activity
CA3000396A1 (fr) Anticorps antagonistes se liant specifiquement au cd40 humain et procedes d'utilisation
JP2020517699A (ja) ジスルフィド結合の還元を最小限にする抗体製造法
MX2008012843A (es) Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
AU2003282160A1 (en) Antibody for adcc and inducing cytokine production
KR20130028055A (ko) Ｃｄ １２７ 결합 단백질
JP6850351B2 (ja) 抗体のインビトロ糖鎖工学
JP2012517806A (ja) ヒト化抗ｃｄ２０抗体および使用方法
EA039084B1 (ru) Антитела к tl1a и их применения
CN113396162A (zh) 抗IL-7Rα亚基的抗体及其用途
WO2019184935A1 (fr) Anticorps anti-cd27, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
TW202039849A (zh) 在產生抗cd38抗體之期間微量金屬的控制
AU2004283925A1 (en) Use of metallic cations to improve functional activity of antibodies
CN116234826A (zh) Btla抗体
JP7014783B2 (ja) 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用
Jefferis The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
US11987624B2 (en) Human monocarboxylate transporter 1 antibodies and uses thereof
CN118043353A (zh) 人单羧酸转运蛋白1抗体及其用途
EA040943B1 (ru) Антитела к cd154 и способы их применения
MAURER et al. Patent 2971732 Summary

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LFB BIOTECHNOLOGIES

Free format text: FORMER APPLICANT(S): LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application